Results 61 to 70 of about 15,641 (133)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, Volume 86, Issue 8, Page 882-890, June 2026.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source

Development of Prostate Cancer Intramuscular Metastasis During 177 Lu-PSMA-617 Treatment. [PDF]

Clin Nucl Med
Xie VK, Jahromi AH.
europepmc   +1 more source

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 9, Page 1043-1052, June 15, 2026.
ABSTRACT Purpose Previous studies have demonstrated an association between PSMA‐PET SUVmax and poorer survival outcomes in patients with mCRPC. However, limited data are available in mHSPC. We aim to investigate the relationship between baseline PSMA‐PET SUVmax and rPFS in patients with mHSPC.
Cevat İlteriş Kıkılı, Caner Kapar, Feyyaz Hazar Yağmur, Esra Arslan, Bahadır Köylü, Fatih Kemik, Buğra Han Esen, Nazan Demir, İlkay Gültürk, Murat Polat, Fatih Selçukbiricik, Deniz Tural   +11 more
wiley   +1 more source

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target

The Prostate, Volume 86, Issue 9, Page 1061-1068, June 15, 2026.
ABSTRACT Introduction The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.
Jacky T. F. Luk, Alex H. Lin, Esther K. C. Cheung, Renald Meçani, Taulant Muka, Jana Nano, Joanna K. M. Ng, Matthew K. L. Chiu, Bryan C. W. Li, Rong Na, Joshua J. X. Li   +10 more
wiley   +1 more source

Extracellular vesicles as mediators of prostatic diseases: connecting function to diagnostic and therapeutic applications. [PDF]

Extracell Vesicles Circ Nucl Acids
Bishara J, Morakinyo M, Saini S.
europepmc   +1 more source

Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival

Statistics in Medicine, Volume 45, Issue 13-14, June 2026.
ABSTRACT Understanding the mechanisms through which anti‐cancer treatments influence survival is central to improving drug development and evaluation. In this work, we develop a Bayesian joint modeling framework for mediation analysis to quantify the extent to which tumor size dynamics mediate the effect of treatment on overall survival (OS). Our model
Georgios Kazantzidis, Francois Mercier, Virginie Rondeau   +2 more
wiley   +1 more source

Comparative Analysis of ISM-1 and B7-H3 Expression in Castration-Resistant Prostate Adenocarcinoma: Associations with Tumor Aggressiveness and Resistance Dynamics. [PDF]

Medicina (Kaunas)
Kaya Ş, Öztürk A, Yüceer RO, Öztürk NB.   +3 more
europepmc   +1 more source

Identification of genetically predicted protein biomarkers and drug targets for prostate cancer via Mendelian randomization

VIEW, Volume 7, Issue 3, June 2026.
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai, Tianming Peng, Zhiyue Xie, Chuqian Zhen, Chen Yao, Nan Peng, Qianyi Li, Yuzhong Yu, Jiming Bao, Xian‐Lu Song, Mingkun Chen, Shan‐Chao Zhao   +11 more
wiley   +1 more source

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer. [PDF]

Cell Death Dis
Yanushko D, Pichot A, Vincent A, Keime C, Laverny G, Metzger D.   +5 more
europepmc   +1 more source

Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair

British Journal of Pharmacology, Volume 183, Issue 11, Page 2947-2968, June 2026.
Background and Purpose Endometriosis is a chronic, hormone‐dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, its impact on lesion regression is limited, possibly due to apoptosis resistance and ...
Yujie Peng, Meng Zhang, Libo Zhu, Wenqiang Qian, Jingjing Yan, Huidi Jiang, Yu Xin, Ying Zhang, Dongli Sun, Weidong Fei, Mengdan Zhao   +10 more
wiley   +1 more source